Free Trial
OTCMKTS:BIOVF

Swedish Orphan Biovitrum Q2 2025 Earnings Results & Report

Swedish Orphan Biovitrum logo
$45.72 0.00 (0.00%)
As of 11/6/2026

Swedish Orphan Biovitrum beat analyst expectations on both earnings and revenue in its Q2 2025 results, released July 16, 2025. The company reported EPS of $0.24 versus the $0.18 consensus estimate, while revenue of $649.61 million topped the $644.68 million estimate by $4.93 million.

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
Before Market Opens

Swedish Orphan Biovitrum EPS Results

Actual EPS
$0.24
Consensus EPS
$0.18
Beat/Miss
Beat by +$0.06
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 8 quarters

Swedish Orphan Biovitrum Revenue Results

Actual Revenue
$649.61 million
Expected Revenue
$644.68 million
Beat/Miss
Beat by +$4.93 million
YoY Revenue Growth
N/A

Conference Call Resources

Swedish Orphan Biovitrum Q2 2025 Earnings FAQ

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) reported earnings of $0.24 per share for Q2 2025, beating the consensus estimate of $0.18. The report was announced on Wednesday, July 16, 2025.

Swedish Orphan Biovitrum reported revenue of $649.61 million for Q2 2025, against a consensus estimate of $644.68 million.

Swedish Orphan Biovitrum Earnings Headlines

Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
See More Swedish Orphan Biovitrum Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Swedish Orphan Biovitrum? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Swedish Orphan Biovitrum and other key companies, straight to your email.

About Swedish Orphan Biovitrum

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) AB, known as Sobi, is a Swedish biopharmaceutical company focused on developing and providing treatments for rare and other serious diseases. Its work centers on hematology, immunology and specialized medicines for conditions with limited treatment options.

Sobi’s portfolio includes therapies for blood disorders such as hemophilia, as well as treatments for rare inflammatory and immune-related conditions. The company also develops and commercializes medicines for other rare diseases, working with research and commercial partners where appropriate.

The company was formed in 2010 when Biovitrum acquired Swedish Orphan and adopted the Swedish Orphan Biovitrum name. Based in Sweden, Sobi serves patients through operations and partnerships across Europe, North America and other international markets.

View Swedish Orphan Biovitrum Profile